Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Greenberg

Showing results (1-10 of 148) with videos related to

Pageof 15
Sort By:
Lancet (London, England)|May 19, 2004
Bush accused of financially neglecting research. Below-inflation investment increases will rob USA of scientific dominance, claim expertsDan Greenberg
Lancet (London, England)|October 16, 2003
Prospects fade for drug benefit for US elderly. Costly legislation appears dead in face of record deficit and grim economic newsDan Greenberg
Lancet (London, England)|March 23, 2004
New report accuses Bush of suppressing research data. Allegations prompt defensive response; White House blames "poor communication"Dan Greenberg
BMC Health Services Research|June 2, 2022
Public legitimacy of healthcare resource allocation committees: lessons learned from assessing an Israeli case studyYael Assor, Dan Greenberg
Health Policy (Amsterdam, Netherlands)|June 27, 2008
Estimating the budget impact of new technologies added to the National List of Health Services in Israel: stakeholders' incentives for adopting a financial risk-sharing mechanismAriel Hammerman, Dan Greenberg
Expert Review of Pharmacoeconomics & Outcomes Research|March 10, 2017
Using lower cost statins improves outcomes for normal cholesterol non-diabetic patientsRonen Arbel, Dan Greenberg
Journal of Medical Economics|May 20, 2009
Clinical trials and health economics--a marriage of convenience or a marriage made in heaven?Ameet Bakhai, Dan Greenberg
International Journal for Equity in Health|February 26, 2016
Rethinking cost-effectiveness in the era of zero healthcare spending growthRonen Arbel, Dan Greenberg
Clinicoeconomics and Outcomes Research : CEOR|October 23, 2014
A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseasesShmuel Odes, Dan Greenberg
Harefuah|September 21, 2012
[Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals]Ariel Hammerman, Dan Greenberg
Pageof 15

Showing results (1-10 of 148) with videos related to

Sort By:
Pageof 15
Lancet (London, England)|May 19, 2004
Bush accused of financially neglecting research. Below-inflation investment increases will rob USA of scientific dominance, claim expertsDan Greenberg
Lancet (London, England)|October 16, 2003
Prospects fade for drug benefit for US elderly. Costly legislation appears dead in face of record deficit and grim economic newsDan Greenberg
Lancet (London, England)|March 23, 2004
New report accuses Bush of suppressing research data. Allegations prompt defensive response; White House blames "poor communication"Dan Greenberg
BMC Health Services Research|June 2, 2022
Public legitimacy of healthcare resource allocation committees: lessons learned from assessing an Israeli case studyYael Assor, Dan Greenberg
Health Policy (Amsterdam, Netherlands)|June 27, 2008
Estimating the budget impact of new technologies added to the National List of Health Services in Israel: stakeholders' incentives for adopting a financial risk-sharing mechanismAriel Hammerman, Dan Greenberg
Expert Review of Pharmacoeconomics & Outcomes Research|March 10, 2017
Using lower cost statins improves outcomes for normal cholesterol non-diabetic patientsRonen Arbel, Dan Greenberg
Journal of Medical Economics|May 20, 2009
Clinical trials and health economics--a marriage of convenience or a marriage made in heaven?Ameet Bakhai, Dan Greenberg
International Journal for Equity in Health|February 26, 2016
Rethinking cost-effectiveness in the era of zero healthcare spending growthRonen Arbel, Dan Greenberg
Clinicoeconomics and Outcomes Research : CEOR|October 23, 2014
A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseasesShmuel Odes, Dan Greenberg
Harefuah|September 21, 2012
[Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals]Ariel Hammerman, Dan Greenberg
Pageof 15